PTJ
PTGX icon

Paul Tudor Jones’s Protagonist Therapeutics PTGX Stock Holding History

Paul Tudor Jones’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$454K Sell
3,700
-2,500
-40% -$261K ﹤0.01% 2891
2026
Q1 		$653K Buy
6,200
+2,700
+77% +$239K ﹤0.01% 2651
2025
Q4 		$306K Buy
+3,500
New +$286K ﹤0.01% 3040

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Paul Tudor Jones's PTGX Position: Q1 2026 in Review

Paul Tudor Jones sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 7,718 shares — an estimated $683K sold.

Paul Tudor Jones first reported a position in PTGX in Q3 2022 and held it in 8 quarters. The position peaked at $2.06M in Q1 2025. 319 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Paul Tudor Jones reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Paul Tudor Jones sold 7,718 Protagonist Therapeutics shares in Q1 2026, an estimated $683K.
  • Paul Tudor Jones first reported a position in Protagonist Therapeutics in Q3 2022 and held it in 8 quarters.
  • Paul Tudor Jones's Protagonist Therapeutics position peaked at $2.06M in Q1 2025.
  • 319 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Tudor Investment Corp's 13F filing for Q1 2026, filed 15 May 2026.